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A B S T R A C T
Novel amidinourea derivatives have been synthesised and evaluated for their antiviral activity against Hepatitis
C Virus (HCV). A compound with an amidinourea-spermine chemical structure, different from that of standard
anti-HCV drugs, showed micromolar activity against HCV and excellent viability. Studies on the mode of action
revealed that the new compound may act against HCV through the inhibition of IRES-mediated translation.
Hepatitis C Virus (HCV) infection represents a disease of significant
global impact that afflicts around 170 million people worldwide.1,2 A
small proportion of infected people clear the virus naturally,3 whilst the
majority develop chronic hepatitis C (CHC) which can lead to a spec-
trum of liver diseases from mild inflammation to extensive liver fibrosis
and cirrhosis, conferring significant morbidity and mortality to affected
individuals.4 The world health organization (WHO) estimates that
globally around 200 million people are chronically infected with HCV,
with 3–4 million new infections occurring every year.5 The standard
therapy for HCV infection has been based for more than a decade on the
use of pegylated interferon alpha (PEG-IFNα) and the antiviral nu-
cleoside analogue ribavirin (RBV).6 Since 2011, a number of directly
acting antivirals (DAAs), such as the protease inhibitors (PIs) telaprevir,
boceprevir and simeprevir,7 and the viral RNA-dependent RNA poly-
merase inhibitor sofosbuvir,8–9 have been licensed for use as part of
combination therapies for HCV and CHC infections. These innovative
treatment regimens have revolutionized the field of HCV medicine and
provided optimism to find a cure in HCV patients. However, the fight
against HCV infections is not fully over yet, because of the high costs
associated with the therapies as well as the emergence of mutant strains
resistant to DAA drugs.10–12
We recently reported the design and discovery of new amidinourea
HCV inhibitors with structure A (Fig. 1), as analogues of the antiviral
drug moroxydine.13 As a continuation of this work, the synthesis and
biological evaluation of a new series of amidinourea14 derivatives with
general structure B was planned. Since the natural polyamines15 sper-
mine, spermidine and putrescine were recently reported to possess in-
hibitory activity against HCV,16 we became intrigued by the possibility
to merge both the amidinourea and the polyamine moieties into a hy-
brid structure. This resulted in the design of a series of amidinourea-
polyamine hybrids with general structure B (Fig. 1).
In this work, the synthesis, biological evaluation and mode of action
studies of new polyamine amidinourea B as inhibitors of HCV is de-
scribed.
The synthesis of a set of amidinourea compounds derived from the
diamines putrescine 1a and 1,8-diaminooctane 1b was first planned.
The diamines 1a–b were reacted with N,N′-di-Boc-S-methylisothiourea
in DCM at room temperature affording the Boc-guanidines 2a–b.17 The
latters were reacted with an appropriate amine (allylamine, benzyla-
mine and p-Cl-aniline) and then treated with HCl/AcOEt solution to
afford the corresponding amindinoureas 3a–c. Scheme 1. Putrescine
was also converted into the monoguanidine derivative 4 which in turn
led the amidinoureas 5 and 6 through reaction with allylamine, benzoyl
chloride and Boc deprotection as shown in Scheme 1. The choice of an
allyl substituent on the amidinourea moiety arose from preliminary
data and previous work on similar amidinourea derivatives endowed
with antimicrobial activity.18,19
Amidinoureas 8a–b bearing a spermine and spermidine backbone
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respectively were synthesised in a similar way as reported in Scheme 1.
The guanylated intermediates 7a–b, obtained via guanylation of the
appropriate polyamine, were reacted with allyamine in refluxing THF
affording, after Boc deprotection, the derivatives 8a–b. The secondary
amine groups in 7a were also converted into tertiary amines via re-
ductive amination reaction leading to 9, in order to explore the im-
portance of an NH moiety for the antiviral activity. The reaction of 9
with allyl amine and Boc-deprotection led to amidinourea 10.
Finally, a set of guanidine derivatives 13a–b and 15a–b were syn-
thesised as described in Scheme 2 with the aim to evaluate a correlation
between the presence of an amidinourea moiety on a polyamine
backbone with the antiviral activity. The alkylated S-methylisothiourea
derivatives 12a–c were synthesised via Mitsunobu reaction according
to previously reported procedures.24 Reaction of 12a–c with 1,8-dia-
minooctane 1b and the triamine 14, followed by Boc cleavage with
HCl/AcOEt led to guanidine derivatives 13a–b and 15a–b.
All the compounds 3a–c, 5, 6, 8a–b, 10, 13a–b and 15a–b were
assayed for their potential cytotoxicity at a single dose of 10 µM on
Huh7 cells. Interestingly, all compounds proved to be non toxic, with
the exception of 3a and 3b which exhibited high cellular toxicity and
therefore were excluded from further experiments (Fig. 2a). The non-
cytotoxic compounds were then assayed as potential HCV antiviral
agents, specifically as potential HCV entry or replication inhibitors.
Initially, the antiviral activity of amidinourea and guanidine
derivatives on HCV entry using HCV pseudo-particles (HCVpp) at a
single dose of 10 µM was evaluated. All the compounds showed no
entry effect, in contrast with the great inhibition detected from the
positive control bafilomycin (Fig. 2b). The same compounds were then
tested on HCV transient replication using a sub-genomic HCV replicon.
Accordingly, Huh7 cells were electroporated with HCV RNA and seeded
in the presence of the potential inhibitors at the concentration of 10 µM
for 24 h. As shown in Fig. 2c, the spermine-amidinourea derivative 8a
was the sole active molecule, exhibiting a strong antiviral activity
(90%). Since only one compound showed antiviral activity, a Structure
Activity Relationship (SAR) study was not possible. However, it looks
clear that the anti-HCV activity must be associated to the presence of a
spermine backbone mainly. Moreover, the amine groups in the sper-
mine chain must be secondary, as no activity was observed for the
tertiary amine derivative 10.
However, despite the disappointing screening results, the amidi-
nourea 8a showed an excellent antiviral profile and thus it was further
characterised performing a full dose response scale on the transient
replication using a starting concentration of 30 µM, following 1:3 di-
lutions (Fig. 3a). A significant dose dependency was observed, with an
IC50 of 2.65 µM. Again, no effects on the cellular viability were de-
tected, except a modest toxic effect at 30 µM.
Based on the results of the initial screening which showed a good
inhibitory activity and low toxicity for 8a, and intrigued by its in-
novative and uncommon chemical structure when compared to stan-
dard anti-HCV agents, we decided to further investigate this compound
try to elucidate its mode of action.
We initially validated our findings by evaluation of compound 8a on
the fully infectious HCV cell-cultured, using the JFH-1 clone.20 Fol-
lowing viral inoculation for 3 h, Huh7-J20 infected cells were exposed
to 8a treatment for a period of 72 h with the same dose–response
concentrations tested for transient replicons. A good cellular viability
was observed, with a moderate cytotoxicity detected only at the con-
centration of 30 µM and a predicted CC50 value of 81.1 µM. The com-
pound also showed a good antiviral activity on fully infectious HCV
cell-cultured, with an IC50 value of 12.3 µM (Fig. 3b), in line with the
antiviral effect observed on the HCV replicon. In order to understand
whether the slightly reduced antiviral activity of 8a was due to a
structure-related issue affecting the drug entry or drug stability or to a
different mechanism of action, the amidinourea 8a was re-tested
against the transient replicon at the concentration of 10 µM, allowing
the replication to establish for 24 h before treating with 8a for an ad-
ditional 24 h. Interestingly, a reduced antiviral activity (∼45%, Fig. 4a)
compared to immediate exposure to the compounds (∼90%) was ob-
served, suggesting a potential role of 8a in the early stage of HCV re-
plication. With the aim to explore this hypothesis, Huh7 cells trans-
fected with wild-type replicon RNA (WT) were seeded in the presence
of the compound 8a and monitored at 2, 4, 8 and 24 h. Interestingly, a
strong antiviral phenotype was observed after only 2 h and maintained
throughout the experiment (Fig. 4b). Thus, we decided to evaluate the
efficacy of 8a against a replication-defective replicon (GND), which,
once transfected, is only able to be translated to generate mature pro-
teins, resulting in a loss of signal in 24 h. As it is evident from Fig. 4c, 8a
exhibited a consistent antiviral activity against GND, showing a con-
stant reduction from 2 to 8 h post-transfection. Comparing inhibition
levels between WT and GND showed the same antiviral efficacy at
Fig. 1. Structure of polyamines and anti-HCV amidinoureas.
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every time point considered (Fig. 4d), suggesting that the antiviral ef-
fect of 8a is exerted through the inhibition of viral translation. We fi-
nally evaluated the effect of 8a on a stable replicon cell line, persis-
tently expressing HCV subgenomic genome (Huh7-J17).21 A moderate
effect was detected on viral replication, with the maximal antiviral
effect exerted in the first 24 h (45%) (Fig. 4e).
It was speculated that 8a could affect the protein translation or
processing in the HCV replication cycle. The viral protein processing
was thus investigated, to establish whether the HCV inhibition was
determining an increased amount of unprocessed polyprotein, due to a
block in the processing, or a reduced amount of mature protein, in-
dicating in this case an impaired translation.
For this purpose, Huh7 cells, transfected with HCV replicon RNA,
were treated with 8a for 8 or 24 h and then assayed by western blot to
evaluate the viral protein NS5A. As reported in Fig. 4f, we detected a
significantly reduced amount of NS5A, while no accumulation of un-
processed polyprotein was detected, suggesting a role for 8a in affecting
viral translation. To confirm our hypothesis, the effect of 8a on the HCV
IRES-mediated translation was finally evaluated. To this scope, Huh7
cells were co-transfected with two plasmids: 1) one expressing firefly
luciferase under the control of HCV IRES and 2) another expressing
Scheme 1. Synthesis of amidinoureas derivatives 3a–c, 5, 6, 8a–b and 10.
Scheme 2. Synthesis of guanylated polyamines 13a–b and 15a–b.
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renilla firefly under the control of TK promoter to normalise data for
transfection efficiency. Cells were exposed to 8a for 24 h before as-
saying for dual luciferase. Results showed a moderate, although sig-
nificant, inhibition (40%, Fig. 4g) of firefly translation, supporting the
hypothesis that 8a is controlling HCV replication through a modulation
of its IRES-mediated translation. It is noteworthy, that some of the
known HCV IRES inhibitors described in the literature to date bear a
guanidine/bis-guanidine moiety,22–24 clearly indicating a key role of
this, and similar groups like amidinoureas, for antiviral activity.
In conclusion, a novel inhibitor 8a of HCV, with a novel amidi-
nourea-spermine structure, has been identified. The new compound 8a
disclosed with this work showed a good antiviral profile and excellent
viability. Preliminary studies on the mode of action suggest that com-
pounds 8a could inhibit HCV by modulating the RNA IRES translation.
Further studies are in progress in our labs to fully confirm the mode of
Fig. 2. Antiviral activity and cytotoxicity of amidinourea and guanidine com-
pounds. a) Huh7 cells were treated with 10 μM of each compound and in-
cubated for 24 h before evaluating cell viability. b) Huh7 cells were treated with
each compound and the concentration of 10 μM for 1 h and then infected with
HCVpp for 3 h in the presence of the compounds. Viral entry was detected 72 h
post infection. c) Huh7 cells, electroporated with HCV subgenomic RNA, were
seeded and treated with 10 μM of each compound for 24 h before measuring
luciferase.
Fig. 3. Dose response scale curves for amidinourea 8a on HCV replicon or
HCVcc. a) Huh7 cells were electroporated with HCV replicon RNA and exposed
to 8a for 24 h. b) Huh7-J20 cells were infected with fully infectious HCV
(JFH1), treated for 72 h and then harvested to evaluate viral replication. Grey
dots and line: cellular viability; black dots and line: viral replication.
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action and to design analogues of 8a bearing a spermine backbone to be
tested against wild-type and resistant HCV.
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Fig. 4. Effect of amidinourea 8a on early stage of viral replication and on initial processing and IRES-mediated translation. a) Huh7 cells were electroporated with
HCV subgenomic RNA and immediately treated with 8a (left bar) or incubated for 24 h before being treated with 8a for 24 h (centre bar). b and c) Time course of 8a
on HCV replicon (b) or replication defective GND (c). Huh7 cells were transfected with HCV RNA and seeded in the presence of 8a. Viral replication/translation was
evaluated at 2, 4, 8 and 24 h post transfection. d) Antiviral effect of 8a at each time point evaluated compared to untreated cells. e) Huh7 cells, stably expressing HCV
replicon RNA, were treated with 8a and the viral replicon was evaluated at 24, 48 and 72 h. f) Huh7 cells were transfected with HCV replicon RNA and immediately
treated with 8a for 8 or 24 h. g) Huh7 were transfected with a plasmid encoding for firefly luciferase under the control of HCV IRES and co-transfected with a plasmid
encoding for the Renilla luciferase to normalise for transfection efficiency.
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